Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Outlook for Nvidia and AMD under Trump’s chip plan
stocks
Has the ‘Buffett premium’ gone away for Berkshire?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,117.60 | 41.00 | 0.45% |
CAC 40 | 7,698.52 | 44.48 | -0.57% |
DAX 40 | 24,081.34 | 81.52 | -0.34% |
Dow JONES (US) | 43,975.09 | 200.52 | -0.45% |
FTSE 100 | 9,129.71 | 33.98 | 0.37% |
HKSE | 24,906.81 | 47.99 | 0.19% |
NASDAQ | 21,385.40 | 64.62 | -0.30% |
Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
S&P 500 | 6,373.45 | 16.00 | -0.25% |
S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
SSE Composite Index | 3,647.55 | 12.42 | 0.34% |